ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Efficacy and Safety of Ischemia-Free Liver Transplantation (IFLT) in the Treatment of End-Stage Liver Disease in a Prospective, Randomized, Controlled Trial: A Report of the First 25 Cases

X. He, Z. Guo, Q. Zhao, C. Huang, W. Ju, D. Wang, M. Chen, L. Wu, Y. Ma, Y. Chen, A. Hu, X. Zhu

Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Meeting: 2020 American Transplant Congress

Abstract number: 594

Keywords: Efficacy, Ischemia, Liver transplantation, Safety

Session Information

Session Name: All Organs: Organ Preservation/Ischemia Reperfusion Injury

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

*Purpose: We’ve established a novel procedure called ischemia-free liver transplantation (IFLT). The results from the pilot study suggest that IFLT might prevent ischemia-reperfusion injury (IRI) and yield better transplant outcomes in comparison to conventional liver transplantation (CLT). The purpose of this study was to further explore the efficacy and safety of IFLT in a prospective, randomized, controlled trial.

*Methods: This is an investigator initiated, open-label, phase-III, prospective, single-center randomized, controlled trial on the effects of IFLT in patients with end-stage liver disease. The primary endpoint is the incidence of early allograft dysfuncion (EAD) after liver transplantation. After 12-month follow-up of the last enrolled recipient, the outcomes will be analyzed to evaluate the safety and efficacy of IFLT versus CLT in patients with end-stage liver disease. We aimed to recruit 34 cases in each arm.

*Results: By December 1st, 2019, a total of 25 patients have been enrolled in the trial (12 in CLT group and 13 in IFLT group). The perfusion parameters and blood gas results showed that the perfusion remained stable and the livers functioned well during IFLT procedures. Of the 13 patients in the IFLT group, 1 (7.7%) suffered from EAD and 0 suffered from PNF, and compared with 3 (25%) suffered from EAD and 1 suffered from primary non-function (PNF) in the CLT group. No recipient died in the IFLT group, while one died from PNF in the CLT group. Besides, the IFLT group was associated with less liver graft injuries [peak aspartate aminotransferase levels, 532.92 (205-1484) versus 1382.55 (232-4260) U/L, P = 0.0283; peak alanine aminotransferase levels, 195.31 (93-437) versus 492.73 (105-1330) U/L, P = 0.0343]. The total bilirubin level on postoperative day 7 in the IFLT group was 2.64 (0.63-11.64) mg/dL compared with 4.90 (0.99-15.44) mg/dL in the CLT group (P= 0.1463). The pre-albumin level on postoperative day 7 in the IFLT group was 171.38 ± 39.81 mg/L compared with 148.91 ± 38.51 mg/L in the CLT group (P = 0.1758 ). The gamma-glutamyl transpeptidase level on postoperative day 7 in the IFLT group was 184.23 (29-465) U/L compared with 220.73 (59-476) U/L in the CLT group (P= 0.5068).

*Conclusions: The preliminary results of our trial suggests that IFLT is reliable and provides a novel approach to minimize graft IRI. The final results of this first randomized trial are pending.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

He X, Guo Z, Zhao Q, Huang C, Ju W, Wang D, Chen M, Wu L, Ma Y, Chen Y, Hu A, Zhu X. The Efficacy and Safety of Ischemia-Free Liver Transplantation (IFLT) in the Treatment of End-Stage Liver Disease in a Prospective, Randomized, Controlled Trial: A Report of the First 25 Cases [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-efficacy-and-safety-of-ischemia-free-liver-transplantation-iflt-in-the-treatment-of-end-stage-liver-disease-in-a-prospective-randomized-controlled-trial-a-report-of-the-first-25-cases/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences